Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.Da3GqCks.js ...

The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine ...

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new targeted chemotherapy drug for ...

The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

No previous study has investigated whether glucarpidase improves important clinical outcomes in patients with methotrexate-associated acute kidney injury (AKI).

Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...

For a child battling cancer, an unexpectedly high temperature can initiate a race against time to reach providers who can ...

Researchers say lerociclib plus fulvestrant could become a new treatment option for HR+/HER2- advanced breast cancer, but lerociclib is not approved in the US.